Harold Keer
Impact in
- Cancer Research top 5%
- Cancer, Lipids, and Metabolism
-
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
Papers in
- Hematology 16
- Acute Myeloid Leukemia Research 14
- Co-authors
- Amy E. SpoonerMary‐Ellen TaplinGlenn J. BubleySteven P. BalkTodd D. ShusterHau C. KwaanJames M. KozlowskiStewart W. McCallum
- Journals
- Blood (11 papers)Journal of Clinical Oncology (10 papers)Annals of Oncology (6 papers)Cancer Research (6 papers)Clinical Cancer Research (5 papers)
- Partner nations
- United StatesItalyCanada
In The Last Decade
Harold Keer
72 papers receiving 2.5k citations
Hit Papers
Peers
Comparison fields: 5 of 96
- Cancer Research 610
- Pulmonary and Respiratory Medicine 1.2k
- Hepatology 219
- Oncology 627
- Endocrinology, Diabetes and Metabolism 371
Countries citing papers authored by Harold Keer
This map shows the geographic impact of Harold Keer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harold Keer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harold Keer more than expected).
Fields of papers citing papers by Harold Keer
This network shows the impact of papers produced by Harold Keer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harold Keer. The network helps show where Harold Keer may publish in the future.
Co-authors
The 25 scholars most cited alongside Harold Keer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 8 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 2 | |
| 6 | 2024 | 1 | |
| 7 | 2023 | 22 | |
| 8 | 2023 | 7 | |
| 9 | 2023 | 3 | |
| 10 | 2020 | 30 | |
| 11 | 2019 | 31 | |
| 12 | 2018 | 46 | |
| 13 | 2018 | 19 | |
| 14 | 2018 | 95 | |
| 15 | 2018 | 11 | |
| 16 | 2017 | 78 | |
| 17 | 2015 | 73 | |
| 18 | 2012 | 70 | |
| 19 | A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC). | 2007 | 7 |
| 20 | A Phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL880, a VEGFR and MET kinase inhibitor, administered daily to patients (pts) with advanced malignancies | 2007 | 8 |
About Harold Keer
Harold Keer is a scholar working on Hematology, Cancer Research, Molecular Biology, Oncology and Pulmonary and Respiratory Medicine, having authored 75 papers that have together received 2.6k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (14 papers), Epigenetics and DNA Methylation (11 papers), Histone Deacetylase Inhibitors Research (8 papers), Pneumocystis jirovecii pneumonia detection and treatment (6 papers), Ubiquitin and proteasome pathways (6 papers), Lung Cancer Treatments and Mutations (6 papers), Fibroblast Growth Factor Research (5 papers) and RNA modifications and cancer (5 papers). The work is most often cited by research in Cancer Research (610 citations), Pulmonary and Respiratory Medicine (1.2k citations), Hepatology (219 citations), Oncology (627 citations) and Endocrinology, Diabetes and Metabolism (371 citations). Harold Keer has collaborated with scholars based in United States, Italy and Canada. Frequent co-authors include Amy E. Spooner, Mary‐Ellen Taplin, Glenn J. Bubley, Steven P. Balk, Todd D. Shuster, Hau C. Kwaan, James M. Kozlowski, Stewart W. McCallum, Patricia LoRusso and Kenneth P. Nephew. Their work appears in journals such as Blood, Journal of Clinical Oncology, Annals of Oncology, Cancer Research and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.